Two other frequent ADHD treatments named methylphenidate and lisdexamfetamine dimesylate also remain in scarcity, according to the agency's data, Because the FDA initial declared supply shortfalls in July previous 12 months. "We have not been equipped to acquire sufficient raw product to commercialize the products at complete commercial scale, and